Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial
Table 9
Outcomes at baseline and the end of study.
Outcomes
ACE group (n = 108)
Sham ACE group (n = 108)
Z
Waistline, median (IQR) (cm)
Baseline
93.25 (87.50, 99.00)
92.00 (88.00, 98.00)
−0.314
0.754
End of treatment (16th week)
85.00 (79.00, 90.00)
89.00 (84.00, 95.00)
4.135
<0.001
End of study (40th week)
85.00 (80.00, 90.00)
89.00 (85.00, 95.00)
4.531
<0.001
Weight, median (IQR) (kg)
Baseline
72.90 (67.45, 80.25)
72.00 (66.30, 80.60)
−0.710
0.478
End of treatment (16th week)
66.15 (61.30, 76.00)
69.60 (65.00, 79.10)
2.490
0.013
End of study (40th week)
67.50 (61.50, 76.00)
70.80 (65.20, 80.00)
2.125
0.034
BMI, median (IQR) (kg/m2)
Baseline
27.42 (25.97, 28.89)
27.49 (25.95, 28.93)
0.186
0.852
End of treatment (16th week)
25.11 (23.85, 26.50)
26.62 (25.59, 28.16)
5.039
<0.001
End of study (40th week)
25.39 (23.74, 26.92)
26.83 (25.37, 28.16)
4.935
<0.001
Hipline, median (IQR) (cm)
Baseline
104.00 (100.00, 108.00)
103.00 (100.00, 107.50)
−0.698
0.485
End of treatment (16th week)
99.45 (96.50, 104.00)
100.00 (98.00, 105.00)
1.894
0.058
End of study (40th week)
100.00 (96.00, 103.00)
101.00 (97.30, 105.50)
2.210
0.027
WHR, median (IQR)
Baseline
90.00 (85.00, 95.00)
90.00 (86.00, 94.00)
0.151
0.880
End of treatment (16th week)
85.00 (81.00, 89.00)
88.00 (84.00, 92.00)
3.298
<0.001
End of study (40th week)
85.50 (80.00, 90.00)
88.00 (85.00, 92.00)
3.250
0.001
PBF, median (IQR) (%)
Baseline
33.10 (30.25, 35.10)
33.15 (30.50, 35.35)
0.420
0.674
End of treatment (16th week)
29.35 (26.50, 32.00)
31.70 (29.50, 34.00)
3.930
<0.001
End of study (40th week)
29.90 (27.10, 32.00)
32.00 (28.50, 34.60)
3.702
<0.001
IWQOL-Lite, median (IQR)
Baseline
58.00 (44.50, 72.00)
53.50 (44.00, 66.50)
−1.045
0.296
End of treatment (16th week)
39.00 (35.00, 60.00)
44.00 (35.00, 59.00)
−0.115
0.908
End of study (40th week)
37.00 (33.00, 48.00)
42.00 (33.00, 58.00)
−1.855
0.064
SF-36, median (IQR)
PF
Baseline
95.00 (85.00, 95.00)
95.00 (90.00, 95.00)
1.206
0.228
End of treatment (16th week)
95.00 (90.00, 100.00)
95.00 (90.00, 100.00)
0.648
0.517
End of study (40th week)
95.00 (90.00, 100.00)
95.00 (90.00, 100.00)
1.289
0.197
RP
Baseline
100.00 (75.00, 100.00)
100.00 (75.00, 100.00)
1.421
0.155
End of treatment (16th week)
100.00 (100.00, 100.00)
100.00 (100.00, 100.00)
−0.217
0.828
End of study (40th week)
100.00 (100.00, 100.00)
100.00 (100.00, 100.00)
0.675
0.500
BP
Baseline
72.00 (62.00, 100.00)
72.00 (62.00, 100.00)
0.145
0.885
End of treatment (16th week)
80.00 (72.00, 100.00)
72.00 (62.00, 100.00)
1.832
0.067
End of study (40th week)
100.00 (62.00, 100.00)
100.00 (62.00, 100.00)
0.869
0.385
GH
Baseline
62.00 (48.50, 76.00)
67.00 (57.00, 77.00)
1.679
0.093
End of treatment (16th week)
67.00 (52.00, 77.00)
72.00 (58.50, 82.00)
−1.067
0.286
End of study (40th week)
72.00 (62.00, 82.00)
67.00 (60.00, 85.00)
0.643
0.520
VT
Baseline
75.00 (65.00, 80.00)
75.00 (65.00, 80.00)
0.144
0.886
End of treatment (16th week)
80.00 (70.00, 85.00)
80.00 (70.00, 85.00)
−0.535
0.593
End of study (40th week)
80.00 (70.00, 85.00)
80.00 (70.00, 85.00)
0.623
0.534
SF
Baseline
100.00 (87.50, 112.50)
100.00 (87.50, 112.50)
0.196
0.844
End of treatment (16th week)
100.00 (87.50, 112.50)
100.00 (87.50, 112.50)
0.126
0.900
End of study (40th week)
100.00 (87.50, 112.50)
100.00 (87.50, 112.50)
0.017
0.986
RE
Baseline
100.00 (66.67, 100.00)
100.00 (66.67, 100.00)
−0.724
0.469
End of treatment (16th week)
100.00 (100.00, 100.00)
100.00 (83.33, 100.00)
0.701
0.483
End of study (40th week)
100.00 (100.00, 100.00)
100.00 (100.00, 100.00)
−0.015
0.988
MH
Baseline
72.00 (64.00, 80.00)
72.00 (64.00, 80.00)
−0.545
0.586
End of treatment (16th week)
72.00 (68.00, 80.00)
76.00 (66.00, 84.00)
−0.604
0.546
End of study (40th week)
76.00 (68.00, 88.00)
76.00 (68.00, 88.00)
0.741
0.459
HAD, median (IQR)
Anxiety
Baseline
4.00 (2.00, 6.00)
4.00 (3.00, 6.00)
1.039
0.299
End of treatment (16th week)
3.00 (2.00, 5.00)
3.00 (2.00, 6.00)
−0.801
0.423
End of study (40th week)
2.00 (1.00, 4.00)
3.00 (1.00, 5.00)
−1.083
0.279
Depression
Baseline
4.00 (2.00, 6.00)
3.00 (2.00, 5.50)
−1.240
0.215
End of treatment (16th week)
3.00 (1.00, 4.00)
3.00 (1.50, 5.00)
−0.574
0.566
End of study (40th week)
2.00 (1.00, 3.00)
2.00 (1.00, 4.00)
−1.610
0.107
SES, median (IQR)
Baseline
33.00 (30.00, 35.00)
32.50 (29.00, 36.50)
0.294
0.769
End of treatment (16th week)
33.00 (30.00, 36.00)
33.00 (30.00, 38.00)
0.416
0.677
End of study (40th week)
35.00 (32.00, 39.00)
34.00 (30.00, 39.00)
1.663
0.096
BMI, body mass index; WHR, waist-to-hip ratio; PBF, percent body fat; IWQOL-Lite, Impact of Weight on Quality of Life-Lite; HAD, Hospital Anxiety and Depression Scale; SF-36, 36-Item Short Form; SES, Self-Esteem Scale.
